Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
出版年份 2013 全文链接
标题
Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
作者
关键词
-
出版物
HEPATOLOGY
Volume 58, Issue 3, Pages 1065-1073
出版商
Wiley
发表日期
2013-03-27
DOI
10.1002/hep.26425
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia
- (2012) Luciana Nardinelli et al. ACTA HAEMATOLOGICA
- Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake
- (2012) Min-Koo Choi et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance
- (2012) Michael Heise et al. BMC CANCER
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
- (2012) A. Villanueva et al. CLINICAL CANCER RESEARCH
- Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
- (2012) J. J.G. Marin et al. CURRENT CANCER DRUG TARGETS
- No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors
- (2012) P. Martinez-Becerra et al. MOLECULAR PHARMACEUTICS
- Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients
- (2012) Linda Tarasova et al. Pharmacogenetics and Genomics
- Acquired resistance to drugs targeting receptor tyrosine kinases
- (2011) Steven A. Rosenzweig BIOCHEMICAL PHARMACOLOGY
- Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma
- (2011) Lars Henrik Jensen et al. Expert Review of Anticancer Therapy
- Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
- (2011) Hiroaki Sugiyama et al. JOURNAL OF GASTROENTEROLOGY
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- (2011) T. Minematsu et al. MOLECULAR CANCER THERAPEUTICS
- DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma
- (2011) Elke Schaeffeler et al. Genome Medicine
- Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
- (2010) J. Marin et al. CURRENT MEDICINAL CHEMISTRY
- Role of Organic Cation Transporter 1, OCT1 in the Pharmacokinetics and Toxicity of cis-Diammine(pyridine)chloroplatinum(II) and Oxaliplatin in Mice
- (2010) Shuanglian Li et al. PHARMACEUTICAL RESEARCH
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Protein structure prediction on the Web: a case study using the Phyre server
- (2009) Lawrence A Kelley et al. Nature Protocols
- OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients
- (2008) Otto Zach et al. LEUKEMIA & LYMPHOMA
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started